$3.45
4.17% today
Nasdaq, Apr 04, 08:47 pm CET
ISIN
US64131A1051
Symbol
STIM

Neuronetics, Inc. Stock price

$3.60
-0.66 15.49% 1M
+2.81 355.70% 6M
+1.99 123.60% YTD
-0.64 15.09% 1Y
+0.47 15.02% 3Y
+2.19 155.32% 5Y
-24.18 87.04% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.34 8.63%
ISIN
US64131A1051
Symbol
STIM

Key metrics

Market capitalization $236.93m
Enterprise Value $303.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.06
P/S ratio (TTM) P/S ratio 3.16
P/B ratio (TTM) P/B ratio 7.23
Revenue growth (TTM) Revenue growth 4.96%
Revenue (TTM) Revenue $74.89m
EBIT (operating result TTM) EBIT $-34.04m
Free Cash Flow (TTM) Free Cash Flow $-32.46m
Cash position $19.67m
EPS (TTM) EPS $-1.37
P/E forward negative
P/S forward 1.59
EV/Sales forward 2.05
Short interest 4.42%
Show more

Is Neuronetics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Neuronetics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Neuronetics, Inc. forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Neuronetics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Neuronetics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
75 75
5% 5%
100%
- Direct Costs 23 23
5% 5%
30%
52 52
5% 5%
70%
- Selling and Administrative Expenses 71 71
4% 4%
95%
- Research and Development Expense 13 13
34% 34%
17%
-32 -32
12% 12%
-43%
- Depreciation and Amortization 2.07 2.07
3% 3%
3%
EBIT (Operating Income) EBIT -34 -34
11% 11%
-45%
Net Profit -43 -43
43% 43%
-58%

In millions USD.

Don't miss a Thing! We will send you all news about Neuronetics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neuronetics, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Policy update increases access for millions covered by Evernorth Health Services Policy update increases access for millions covered by Evernorth Health Services
Positive
Seeking Alpha
6 days ago
Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive re...
Neutral
GlobeNewsWire
8 days ago
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (...
More Neuronetics, Inc. News

Company Profile

Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Head office United States
CEO Keith Sullivan
Employees 716
Founded 1998
Website www.neurostar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today